Loading...
•
Jun 30, 2022
TherapeuticsMD Q2 2022 Earnings Report
Reported solid revenue growth and decreased operating expenses.
Key Takeaways
TherapeuticsMD reported a solid revenue growth of 24% compared to the prior year period and a decrease of 21% in operating expenses. The FDA approved their supplemental new drug application for ANNOVERA, enhancing their ability to meet product demand. They also repaid $120 million of debt using proceeds from the divestiture of their vitaCare unit.
Total net revenue reached $28.6 million.
ANNOVERA TRx reached 9,329, a 28% increase over Q2 2021.
FDA approved the supplemental new drug application for ANNOVERA, enhancing the ability to meet product demand.
The company repaid $120 million of debt with the proceeds from the divestiture of their vitaCare unit.
TherapeuticsMD
TherapeuticsMD
Forward Guidance
The press release contains forward-looking statements that are subject to risks and uncertainties. Actual results and business decisions may differ materially from these statements.
Challenges Ahead
- The company's ability to refinance the indebtedness under its term loan facility
- The company's ability to raise capital to fund its operations
- The impact of the executive order on contraception
- The effects of the COVID-19 pandemic
- The company’s ability to maintain or increase sales of its products